ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1784

Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis

Takeshi Shoda, Tohru Takeuchi, Takaaki Ishida, Hideyuki Shiba, Youhei Fujiki, Daisuke Wakura, Shuzo Yoshida, Takuya Kotani, Shigeki Makino and Toshiaki Hanafusa, Department of Internal Medicine (I), Osaka medical college, Osaka, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Computed tomography (CT), interstitial lung disease, myeloperoxidase (MPO), prognostic factors and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Many patients with interstitial lung disease (ILD) complicated by microscopic polyangiitis (MPA) show a UIP pattern on chest CT. The prognosis is poorer than that of ILD-free MPA(1). However, the details remain to be clarified.

To investigate the prognosis of pulmonary fibrosis with microscopic polyangiitis (MPA-ILD) and prognostic factors.

Methods

Of patients with MPA who were admitted to our hospital between 2001 and 2013 based on the EMEA classification in 2007, the subjects were MPO-ANCA-positive patients with ILD on HRCT. Using the clinical data and fibrosis score on HRCT(2), we examined prognostic factors.

Results

There were 42 patients with MPA-ILD, consisting of 20 males and 22 females, with a median age (interquartile range) of 73 years (range: 69-76 years). The MPO-ANCA, KL-6, Aa-DO2, %FVC, %DLco/VA, and RV/TLC values at the start of treatment were 189 (52-459) EU, 446 (261-615) U/mL, 25.7 (12-34), 81.3 (69-95)%, 61.4 (45-71)%, and 41.1 (33-50)%, respectively. Concerning HRCT images, 30 patients showed a UIP pattern, and 12 showed a non-UIP pattern. PSL was administered to 41 patients. In 37, it was combined with immunosuppressive drugs (CY was used in 16). In 8, apheresis was performed. In 37 patients, the MPO-ANCA level was maintained below the detection limit.

With respect to the prognosis, 8 patients died (exacerbation of interstitial pneumonia: 2, infection and alveolar hemorrhage: 2, pulmonary hypertension: 1, sudden death: 2, and renal failure: 1). The 5- and 10-year survival rates after the start of treatment were 81.6 and 68.0%, respectively.

Univariate analysis using Cox’s proportional hazard model showed that prognostic factors for lung disease-associated death included the HRCT score (p<0.001), CPFE (p=0.025), and administration of CY (p=0.041). However, on multivariate analysis of these factors, the HRCT score was significantly correlated (p=0.006).

Conclusion

Treatment for MPA-ILD was continued, and the prognosis was more favorable than previously reported. Marked fibrosis and CPFE at the start of treatment were considered to be prognostic factors for lung disease-associated death. Immunosuppressive therapy early after onset may improve the prognosis of MPA-ILD.

reference

(1) Fernandez Casares M, Gonzalez A, Fielli M. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol. 2014; May 27.[Epub ahead of print] 

(2) Wells AU, Hansell DM, Rubens MB. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 1997; 40: 1229-36.


Disclosure:

T. Shoda,
None;

T. Takeuchi,
None;

T. Ishida,
None;

H. Shiba,
None;

Y. Fujiki,
None;

D. Wakura,
None;

S. Yoshida,
None;

T. Kotani,
None;

S. Makino,
None;

T. Hanafusa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-factors-for-interstitial-lung-disease-with-microscopic-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology